Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 1/20 | 0.60 |
| ▸ | APLNR | P35414 | 1/20 | 0.60 |
| ▸ | CCR6 | P51684 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.59 |
| ▸ | TOP1 | P11387 | 8/20 | 0.59 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.57 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13007191 | 0.92 | PTPN1 (0.70) | CXCR5APLNRCCR6PTPN1TOP1 | |
| SCHEMBL12944982 | 0.91 | CXCR5 (0.67) | CXCR5APLNRCCR6PTPN1TOP1 | |
| SCHEMBL19360128 | 0.91 | CXCR5 (0.67) | CXCR5APLNRCCR6PTPN1TOP1 | |
| SCHEMBL23584144 | 0.91 | CXCR5 (0.61) | CXCR5APLNRCCR6PTPN1TOP1 | |
| SCHEMBL13007183 | 0.90 | PTPN1 (0.68) | CXCR5APLNRCCR6PTPN1TOP1 | |
| SCHEMBL15393753 | 0.89 | TOP1 (0.62) | CXCR5APLNRCCR6PTPN1TOP1 | |
| SCHEMBL13559837 | 0.89 | TOP1 (0.66) | CXCR5APLNRCCR6PTPN1TOP1 | |
| SCHEMBL15393756 | 0.87 | TOP1 (0.65) | CXCR5APLNRCCR6PTPN1TOP1 | |
| SCHEMBL13867748 | 0.87 | TOP1 (0.65) | CXCR5APLNRCCR6PTPN1TOP1 | |
| SCHEMBL13288192 | 0.86 | TOP1 (0.61) | CXCR5APLNRCCR6PTPN1TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180078482-A1 | COMPOSITION CONTAINING THEASAPOGENOL DERIVATIVE AS ACTIVE INGREDIENT | AMOREPACIFIC CORPORATION (KR) | 2018-03-22 | — | — | US | disclosed |
| US-20180078482-A1 | COMPOSITION CONTAINING THEASAPOGENOL DERIVATIVE AS ACTIVE INGREDIENT | AMOREPACIFIC CORPORATION (KR) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078482-A1 | COMPOSITION CONTAINING THEASAPOGENOL DERIVATIVE AS ACTIVE INGREDIENT | CUTA, USP25, CYP19A1 | CXCR5 3322/4885APLNR 1517/4885CCR6 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.